Hey {{first_name|default:there}}, it’s Vadim 👋
If you've been part of Bio Founder GPS for a while, you know my thesis on “Micro” VCs and emerging fund managers: they're one of the most overlooked sources of capital for early-stage founders.
That's why I was especially excited to sit down with Jonah Probell, founder and managing partner of Lexi Ventures - a seed-stage fund backing the genetic engineering revolution.
To date, Lexi has backed 12 companies, including KiraGen (high-fidelity CRISPR gene editing), Kopra Bio (T-cell immunotherapy for solid tumors), and TippingPoint Therapeutics (precision genetic medicines for rare and neglected pediatric diseases).
As a solo GP investing out of Fund I, Jonah is exactly the kind of investor that thesis points to: small enough that your round genuinely matters to him, and building his own track record hand in hand with the success of the founders that he backs.
🧭 HERE’S WHAT WE COVERED:
How a solo GP actually evaluates a pitch deck
The VC math behind a “yes”
Why genetic engineering could become one of the biggest value-creating venture categories of the decade
And much more!
You can watch the full interview, or listen via your podcast platform of choice below.
Listen + subscribe: Spotify / Apple Podcasts / YouTube
And while you cue those up, here are three takeaways from our conversation to pair with your evening tea ☕